EBV-associated diseases: Current therapeutics and emerging technologies
EBV is a prevalent virus, infecting> 90% of the world's population. This is an oncogenic virus
that causes~ 200,000 cancer-related deaths annually. It is, in addition, a significant …
that causes~ 200,000 cancer-related deaths annually. It is, in addition, a significant …
Promising targets for cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways
K Li, S Qu, X Chen, Q Wu, M Shi - International journal of molecular …, 2017 - mdpi.com
Malignant cancers employ diverse and intricate immune evasion strategies, which lead to
inadequately effective responses of many clinical cancer therapies. However, emerging data …
inadequately effective responses of many clinical cancer therapies. However, emerging data …
Epstein–Barr virus epithelial cancers—A comprehensive understanding to drive novel therapies
Epstein–Barr virus (EBV) is a ubiquitous oncovirus associated with specific epithelial and
lymphoid cancers. Among the epithelial cancers, nasopharyngeal carcinoma (NPC) …
lymphoid cancers. Among the epithelial cancers, nasopharyngeal carcinoma (NPC) …
The role of DNA damage responses in p53 biology
D Speidel - Archives of toxicology, 2015 - Springer
The tumour suppressor p53 is a central player in cellular DNA damage responses. P53 is
upregulated and activated by genotoxic stress and induces a transcriptional programme with …
upregulated and activated by genotoxic stress and induces a transcriptional programme with …
Advanced strategies for therapeutic targeting of wild-type and mutant p53 in cancer
TP53 is a tumor suppressor gene that encodes a sequence-specific DNA-binding
transcription factor activated by stressful stimuli; it upregulates target genes involved in …
transcription factor activated by stressful stimuli; it upregulates target genes involved in …
Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches
O Menyhárt, B Győrffy - Cancer and Metastasis Reviews, 2020 - Springer
Medulloblastoma (MB) is the most common malignant childhood tumor of the brain.
Multimodal treatment consisting of surgery, radiation therapy, and chemotherapy reduced …
Multimodal treatment consisting of surgery, radiation therapy, and chemotherapy reduced …
Relationship between p53 status and the bioeffect of ionizing radiation
X Kong, D Yu, Z Wang, S Li - Oncology letters, 2021 - spandidos-publications.com
Radiotherapy is widely used in the clinical treatment of cancer patients and it may be used
alone or in combination with surgery or chemotherapy to inhibit tumor development …
alone or in combination with surgery or chemotherapy to inhibit tumor development …
Medulloblastoma: optimizing care with a multidisciplinary approach
A Thomas, G Noël - Journal of multidisciplinary healthcare, 2019 - Taylor & Francis
Medulloblastoma is a malignant tumor of the cerebellum and the most frequent malignant
brain tumor in children. The standard of care consists of maximal resection surgery, followed …
brain tumor in children. The standard of care consists of maximal resection surgery, followed …
Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy
Peptide receptor radionuclide therapy (PRRT) is a type of radiotherapy that targets peptide
receptors and is typically used for neuroendocrine tumours (NETs). Some of the key …
receptors and is typically used for neuroendocrine tumours (NETs). Some of the key …
[HTML][HTML] Medulloblastoma: molecular classification-based personal therapeutics
TC Archer, EL Mahoney, SL Pomeroy - Neurotherapeutics, 2017 - Elsevier
Recent advances in cancer genomics have revealed 4 distinct subgroups of
medulloblastomas, each with unique transcription profiles, DNA alterations and clinical …
medulloblastomas, each with unique transcription profiles, DNA alterations and clinical …